ICER set to pass judgement on SMA treatments

24 August 2018

The cost-effectiveness provided by the spinal muscular atrophy (SMA) treatments, Novartis’ (NOVN: VX) AVXS-101 and Biogen’s (Nasdaq: BIIB) Spinraza (nusinersen), is to be assessed by the Institute for Clinical and Economic Review (ICER).

While Spinraza was approved by the US Food and Drug Administration (FDA) to treat SMA in children and adults in 2016, AVXS-101 is a gene therapy being studied for use in infants with SMA that was acquired by Novartis this year. An FDA decision on the latter is due to be made in early 2019.

The ICER’s report on these therapies will be the subject of a March 2019 meeting of the New England Comparative Effectiveness Public Advisory Council, one of ICER’s three independent evidence appraisal committees.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK